Defects in the DNA damage response (DDR) not only promote tumor heterogeneity but also shape the tumor immune landscape through the generation of neoantigens, activation of the cGAS–STING pathway, and modulation of immune checkpoints. This evidence concerns the gene CGAS and neoplasm.